Prostate cancer screening has traditionally relied on a blood test called prostate-specific antigen (PSA), but this approach has significant drawbacks, including unnecessary biopsies and the detection of harmless cancers that may not need treatment. A major new study published in JAMA Oncology analyzed data from 80,114 men across 12 studies to evaluate whether adding magnetic resonance imaging (MRI) to the screening process improves outcomes. The researchers found that MRI-based screening pathways dramatically reduce the number of unnecessary prostate biopsies by up to 81% and decrease the detection of clinically insignificant (harmless) prostate cancers by up to 77%, all while maintaining the same detection rate for clinically significant (dangerous) prostate cancers. This comprehensive meta-analysis provides strong evidence that integrating MRI into prostate cancer screening could fundamentally change how we detect this disease, offering a better balance of benefits and harms for patients.
Prostate cancer is one of the most common cancers affecting men worldwide. For decades, the primary tool for early detection has been the prostate-specific antigen (PSA) blood test. While PSA-based screening has been shown to reduce prostate cancer-specific mortality (death from the disease), it comes with significant downsides that have troubled urologists and patients alike.
The PSA test is not specific to dangerous cancers. Elevated PSA levels can be caused by benign conditions like an enlarged prostate or prostatitis (inflammation of the prostate). This lack of specificity leads to a cascade of potential harms:
To balance these risks and benefits, clinical practice guidelines currently recommend shared decision-making strategies to identify informed candidates who are most likely to benefit from prostate cancer early detection. However, this opportunistic approach has been associated with widespread but untargeted testing, accompanied by disparities in healthcare access and literacy.
Prebiopsy prostate MRI followed by targeted biopsies has been widely integrated into the diagnostic pathway for prostate cancer in recent years. This approach is associated with improved detection of clinically significant prostate cancer and reduced numbers of avoidable biopsies and insignificant cancers in the clinical setting. As a result, clinical practice guidelines have recommended prebiopsy MRI for men with suspected prostate cancer. However, until this study, there was no consensus about the role of MRI as an integrated prostate cancer screening tool for the general population.
This systematic review and meta-analysis was conducted according to the rigorous Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guideline and the Cochrane Handbook. The study protocol was registered on PROSPERO, an international database of prospectively registered systematic reviews.
The researchers conducted a comprehensive search of five major medical databases—PubMed/MEDLINE, Embase, Cochrane/Central, Scopus, and Web of Science—on May 5, 2023. The search identified 2,037 records, of which 1,464 were screened after removing duplicates. After a thorough selection process, 12 studies were eligible for qualitative evidence synthesis, and 8 studies were included in the quantitative meta-analysis.
Eligibility criteria were carefully defined:
Studies were excluded if they addressed diagnostic test accuracy or enrolled preselected men undergoing biopsy (men with lower urinary tract symptoms, elevated PSA levels, or suspicious digital rectal examination results). The meta-analysis was restricted to prospective observational or randomized studies.
For the statistical analysis, the researchers used the generalized mixed-effect approach with pooled odds ratios (ORs) and random-effect models to compare the MRI-based and PSA-only screening strategies. Separate analyses were performed based on the timing of MRI (primary or sequential after a PSA test) and the cutoff for biopsy indication (Prostate Imaging Reporting and Data System [PI-RADS] score of 3 or higher, or 4 or higher).
Two independent reviewers extracted data from eligible studies, including general information, study population characteristics, details of the intervention and comparator, screening algorithm (MRI in first-line or sequential screening), sequence (biparametric [bpMRI] or multiparametric [mpMRI]), type of MRI (1.5T or 3T), PI-RADS cutoff for biopsy indication, type of biopsy approach (targeted plus systematic or targeted only, cognitive or image-fusion), PSA cutoff, and additional novel biomarkers in the screening pathway.
The risk of bias was evaluated according to the Cochrane Collaboration's RoB2 tool for randomized studies and the Risk of Bias in Nonrandomized Studies of Interventions tool for nonrandomized studies. Heterogeneity was assessed by calculating the I² measure and its confidence interval. For all statistical analyses, P ≤ .05 was considered significant.
The study synthesized data from an impressive 80,114 screened men from 12 studies. The included studies comprised 4 population-based randomized clinical trials, 2 prospective cohort studies, and 3 prospective pilot studies. Additionally, 2 studies reported on the efficacy of MRI in a prescreened population, and 4 studies reported data on the use of novel molecular biomarkers combined with MRI in prostate cancer screening.
Most publications included data on the use of MRI as a sequential screening tool (after PSA prescreening); however, 3 studies were identified reporting on up-front MRI. Five studies used biparametric MRI (bpMRI), and 8 included multiparametric MRI (mpMRI). As for the method of biopsy, 7 studies used MRI-targeted only, while 6 studies used additional systematic sampling.
The most striking finding was that compared with standard PSA-based screening, the MRI pathway (sequential screening with a PI-RADS score of 3 or higher cutoff for biopsy) was associated with:
In plain language, this means that MRI-based screening found the same number of dangerous prostate cancers as PSA-only screening, but it did so while performing far fewer biopsies and finding far fewer harmless cancers that would have led to unnecessary worry and treatment.
The researchers synthesized data from 57,081 men derived from 6 articles that applied MRI in a PSA-prescreened population (as part of sequential screening), with a PI-RADS score of 3 or higher as the cutoff for biopsy indication.
The number of men needed to screen to detect 1 significant prostate cancer was 59 for PSA-only screening and 63 for MRI-based strategies. This small difference (59 vs 63) was not statistically significant, confirming that MRI does not miss dangerous cancers.
When the researchers applied alternative definitions for significant cancer (ISUP grade 3 or higher) and insignificant cancer (ISUP grades 1-2), the trends remained similar:
The pooled rate of MRI was 8.5% (95% CI, 2.6%-24.8%; I² = 100%) among the screened individuals, meaning that only about 8.5% of men who underwent PSA testing were referred for MRI. Biopsy adherence was significantly higher when MRI was used (OR, 4.61; 95% CI, 2.39-8.89; P = .01), suggesting that men were more willing to undergo a biopsy when they had a visible suspicious lesion on MRI rather than just an abnormal blood test.
Key diagnostic performance metrics for sequential MRI screening (PI-RADS 3-5 cutoff):
These numbers tell a compelling story. When a man had a suspicious lesion on MRI, there was a 41.9% chance it was a clinically significant cancer—more than 2.5 times higher than the 16.1% chance associated with an elevated PSA test alone. This means that MRI dramatically improved the precision of prostate cancer detection.
The researchers also examined what happened when the threshold for biopsy was raised to a PI-RADS score of 4 or higher (meaning only men with highly suspicious lesions on MRI would undergo biopsy). This approach was associated with even greater reductions in unnecessary procedures:
With a PI-RADS 4 or higher cutoff, the positive predictive value for significant cancer rose to 48.9% (95% CI, 35.4%-62.6%), meaning that nearly half of all men who underwent biopsy based on MRI findings had clinically significant prostate cancer. The biopsy indication rate dropped to just 2.4% (95% CI, 0.9%-6.3%).
To identify the high rate of heterogeneity among the studies and assess the role of possible confounders, the researchers stratified studies based on the type of MRI sequence, biopsy method, and study design. They observed differences in terms of positive predictive value, but not in cancer detection rates or biopsy rates.
Compared with multiparametric MRI (mpMRI), the use of biparametric MRI (bpMRI) was associated with:
This finding is particularly interesting because bpMRI is faster, cheaper, and does not require intravenous contrast injection, making it more feasible for large-scale screening programs.
Regarding biopsy technique, targeted plus systematic biopsies (vs targeted only) and image fusion (vs cognitive) biopsies had a lower positive predictive value for insignificant cancers. This suggests that more precise biopsy techniques can further reduce the detection of harmless cancers.
Three studies evaluated the use of MRI as a primary screening tool (up-front MRI without PSA prescreening), involving 983 men. In this setting:
Due to the limited availability of data, comparison of MRI-based screening with PSA-based approaches was only feasible in terms of biopsy selection, which revealed no significant difference between the 2 strategies (OR, 0.81; 95% CI, 0.23-2.87; P = .50).
Among 19,501 patients who underwent prostate MRI that used a PI-RADS cutoff of 4 or higher, the results were consistent with the overall findings, showing that a higher threshold for biopsy further reduced unnecessary procedures without compromising the detection of dangerous cancers.
The researchers identified 4 articles that reported on the combination of MRI and novel biomarkers (molecular tests that can help identify aggressive prostate cancers). However, given the heterogeneity between populations and interventions within studies, they did not perform a quantitative data synthesis for this subset.
In this subset, the use of novel biomarkers was associated with fewer insignificant prostate cancers while maintaining significant disease detection. Additionally, MRI has been shown to be an effective screening tool in patients with a genetic predisposition for prostate cancer, suggesting that men with a family history or known genetic mutations (such as BRCA mutations) may particularly benefit from MRI-based screening.
The findings of this meta-analysis have profound implications for how prostate cancer screening should be conducted in the future. The evidence strongly supports the integration of prostate MRI into prostate cancer screening pathways to improve the balance of patient harms and benefits.
For patients, this means:
The study also highlights the potential of biparametric MRI (bpMRI), which does not require intravenous contrast and is faster and less expensive than multiparametric MRI. The finding that bpMRI had a higher positive predictive value for significant cancer (61.1% vs 34.8%) suggests that this simpler approach could be particularly well-suited for population-based screening programs.
While this meta-analysis provides compelling evidence, the researchers acknowledged several important limitations:
Based on the findings of this comprehensive meta-analysis, here are actionable recommendations for patients and healthcare providers:
It is important to note that this study does not suggest that PSA testing should be abandoned entirely. Rather, the evidence supports a sequential approach where PSA is used as an initial screening test, and men with elevated PSA levels undergo MRI before deciding whether a biopsy is necessary. This approach preserves the benefits of PSA screening (detecting dangerous cancers) while dramatically reducing its harms (unnecessary biopsies and overdiagnosis of harmless cancers).
The findings also have important implications for healthcare policy and resource allocation. While implementing MRI-based screening requires investment in MRI infrastructure and training, the reduction in unnecessary biopsies and overtreatment could result in significant cost savings and improved patient quality of life.
Adding MRI to prostate cancer screening can reduce unnecessary biopsies by up to 81% and decrease detection of harmless cancers by up to 77%, while still finding the same number of dangerous cancers as PSA-only screening. This means fewer men undergo invasive procedures and avoidable treatments.
PI-RADS is a score from 1 to 5 indicating how suspicious a prostate lesion looks on MRI. Scores 1-2 are low suspicion, while 3, 4, and 5 are intermediate, high, and very high suspicion. A score of 3 or higher is often used as the threshold for biopsy, but using 4 or higher further reduces unnecessary biopsies.
In MRI-based screening, biopsy is typically only performed if a suspicious lesion is seen on MRI (PI-RADS 3 or higher). If your MRI is normal or shows low suspicion (PI-RADS 1-2), you may avoid biopsy altogether, reducing the risk of complications like bleeding or infection.
MRI has a much higher positive predictive value: about 42% for PI-RADS 3 or higher, and nearly 49% for PI-RADS 4 or higher, compared to 16% for an elevated PSA. This means a positive MRI is more likely to indicate a dangerous cancer, leading to more accurate biopsies.
Prostate MRI is non-invasive and does not use radiation. It takes about 30-45 minutes and may require an empty bowel. Some protocols use an endorectal coil, but many use only a surface coil. The test is painless, and you can resume normal activities afterward.
Yes. The study supports a sequential approach: PSA is used as an initial test, and if elevated, MRI is performed before deciding on biopsy. This preserves the benefits of PSA while reducing unnecessary biopsies and overdiagnosis. Discuss with your doctor if MRI-based screening is right for you.
Original Article Title: Magnetic Resonance Imaging in Prostate Cancer Screening A Systematic Review and Meta-Analysis Oncology JAMA Oncology JAMA Network
DOI: 10.1001/jamaoncol.2024.0734
Authors: Tamás Fazekas, MD; Sung Ryul Shim, MPH, PhD; Giuseppe Basile, MD; Michael Baboudjian, MD; Tamás Kói, PhD; Mikolaj Przydacz, MD, PhD, DSc; Mohammad Abufaraj, MD; Guillaume Ploussard, MD, PhD; Veeru Kasivisvanathan, MD, PhD; Juan Gómez Rivas, MD, PhD; Giorgio Gandaglia, MD; Tibor Szarvas, PhD, DSc; Ivo G. Schoots, MD, PhD; Roderick C.N. van den Bergh, MD, PhD; Michael S. Leapman, MD, MHS; Péter Nyirády, MD, PhD, DSc; Shahrokh F. Shariat, MD, DDr(hc); Pawel Rajwa, MD, PhD
Publication: JAMA Oncology, Volume 10, Issue 6, Pages 745-754
Publication Date: Published online April 5, 2024; Published in issue June 1, 2024
DOI: 10.1001/jamaoncol.2024.0734
Funding/Registration: The study protocol was registered on PROSPERO (international prospective register of systematic reviews). The research was conducted according to PRISMA 2020 guidelines and the Cochrane Handbook.
Note: This patient-friendly article is based on peer-reviewed research published in JAMA Oncology. The original study was a systematic review and meta-analysis of 80,114 men from 12 studies, representing the most comprehensive analysis to date of MRI in prostate cancer screening. This article is intended for educational purposes and does not constitute medical advice. Patients should consult with their healthcare providers about prostate cancer screening options.
Use collapsible tabs for more detailed information that will help customers make a purchasing decision.
Ex: Shipping and return policies, size guides, and other common questions.